Adlai Nortye
Pharmaceutical ManufacturingChina51-200 Employees
Adlai Nortye is a pharmaceutical manufacturing company headquartered in China with a global clinical-stage profile focused on cancer therapies. The company maintains dual research and development presence in the United States and China and is developing a pipeline across two main areas: next-generation cancer immunotherapies and RAS-targeting therapies. In cancer immunotherapy, its candidates include AN8025, a tri-functional fusion protein combining αPD-L1, a CD86 variant, and a LAG3 variant, as well as AN4005, an oral small-molecule PD-L1 inhibitor. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a pan-RAS(ON) inhibitor directly to tumors. Adlai Nortye is listed on Nasdaq under ticker ANL and, per provided data, has 51-200 employees and a website at https://adlainortye.com.
1-888-653-2347 
support@leadiq.com 
